Literature DB >> 3759249

[Dosage of imipenem/cilastatin].

P M Shah.   

Abstract

Imipenem/cilastatin was used for the treatment of 594 bacterial infections in 545 patients at a dosage of 1.5 g/day (n = 283), 2.0 g/day (n = 129), 3.0 g/day (n = 102), or 4 g/day (n = 11). The most common indications for therapy were nosocomial pneumonias followed by intraabdominal postoperative infections, and skin and soft tissue infections. Out of 1171 bacterial strains isolated from 932 patients, seven showed primary resistance to imipenem. The causative agent was eliminated in 87% of the patients. Treatment failed in 24 of the 594 patients. In 35 patients therapy was stopped because of side effects. The most frequent side effect was local irritation at the site of intravenous application.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759249     DOI: 10.1007/bf01647499

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Comparison of toxicity of intravenously given local anesthetic agents in man.

Authors:  F F FOLDES; R MOLLOY; P G McNALL; L R KOUKAL
Journal:  J Am Med Assoc       Date:  1960-04-02

2.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

3.  Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci.

Authors:  C Watanakunakorn; J C Tisone
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

Review 4.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 5.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

6.  Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.

Authors: 
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

7.  Imipenem/cilastatin vs. gentamicin/clindamycin for the treatment of moderate to severe infections in hospitalized patients.

Authors:  J G Guerra; E Casalino; J C Palomino; E Barboza; M del Castillo; M Gonzalez del Riego; V Huapaya; E Antúnez de Mayolo
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

8.  Clinical experience with imipenem/cilastatin: analysis of a multicenter study.

Authors:  P M Shah
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

9.  In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.

Authors:  M Díez Enciso; M Mateos Lindemann; A Gutiérrez Altés
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

10.  Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis.

Authors:  J A Indrelie; W R Wilson; J Y Matsumoto; J E Geraci; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

  10 in total
  1 in total

1.  Pharmacokinetics of imipenem in patients undergoing major colon surgery.

Authors:  M Erttmann; R Krausse; U Ullmann
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.